The purpose of the study is to evaluate the safety and performance of the Moderato System by implanting the Moderato pacemaker in patients who require a dual chamber pacemaker, and who also have hypertension, in order to reduce their blood pressure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Moderato Pacing Performance as evaluated through analysis of 24 hour Holter monitoring recordings
Timeframe: 4 months
Moderato Pacing Safety as measured by incidence of of peri-procedural device and treatment-related serious adverse events.
Timeframe: 4 months
Hypertension Treatment Phase Performance as evaluated through analysis of 24 hour Holter monitoring recordings and 24h ambulatory blood pressure.
Timeframe: 3 months
Hypertension Treatment Phase Safety as measured by Incidence of device- and treatment-related serious adverse events through 3 months of treatment
Timeframe: 3 months